These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35096811)

  • 1. Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin's Lymphoma Cells.
    Guo J; He S; Zhu Y; Yu W; Yang D; Zhao X
    Front Cell Dev Biol; 2021; 9():775599. PubMed ID: 35096811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
    Schlapschy M; Gruber H; Gresch O; Schäfer C; Renner C; Pfreundschuh M; Skerra A
    Protein Eng Des Sel; 2004 Dec; 17(12):847-60. PubMed ID: 15708864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
    Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
    Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30
    Hombach AA; Rappl G; Abken H
    Mol Ther; 2019 Oct; 27(10):1825-1835. PubMed ID: 31331813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models.
    Kua L; Ng CH; Tan JW; Tan HC; Seh CC; Wong F; Ong R; Rooney CM; Tan J; Chen Q; Horak ID; Tan KW; Low L
    Mol Ther; 2024 Jun; ():. PubMed ID: 38946142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells.
    Heuser C; Diehl V; Abken H; Hombach A
    Int J Cancer; 2003 Sep; 106(4):545-552. PubMed ID: 12845650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    Cancer Res; 1998 Mar; 58(6):1116-9. PubMed ID: 9515791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma.
    Xu C; Bai Y; An Z; Hu Y; Zhang C; Zhong X
    Mol Ther Oncolytics; 2022 Mar; 24():443-451. PubMed ID: 35141400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3.
    Hombach A; Pohl C; Heuser C; Sircar R; Koch D; Diehl V; Abken H
    Scand J Immunol; 1998 Nov; 48(5):497-501. PubMed ID: 9822258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors.
    Martarelli N; Capurro M; Mansour G; Jahromi RV; Stella A; Rossi R; Longetti E; Bigerna B; Gentili M; Rosseto A; Rossi R; Cencini C; Emiliani C; Martino S; Beeg M; Gobbi M; Tiacci E; Falini B; Morena F; Perriello VM
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
    Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
    J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry.
    Zheng Z; Chinnasamy N; Morgan RA
    J Transl Med; 2012 Feb; 10():29. PubMed ID: 22330761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.
    Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA
    Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms.
    Wu S; Luo Q; Li F; Zhang S; Zhang C; Liu J; Shao B; Hong Y; Tan T; Dong X; Chen B
    Br J Haematol; 2024 Jul; ():. PubMed ID: 38960449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
    Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B
    Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.
    Schlapschy M; Fogarasi M; Gruber H; Gresch O; Schäfer C; Aguib Y; Skerra A
    Protein Eng Des Sel; 2009 Mar; 22(3):175-88. PubMed ID: 19022801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
    Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
    Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
    Fujiwara K; Masutani M; Tachibana M; Okada N
    Biochem Biophys Res Commun; 2020 Jun; 527(2):350-357. PubMed ID: 32216966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.
    Hombach AA; Görgens A; Chmielewski M; Murke F; Kimpel J; Giebel B; Abken H
    Mol Ther; 2016 Aug; 24(8):1423-34. PubMed ID: 27112062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.